Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04727801 · ClinicalTrials.gov registry record
A Clinical Data Collection Study of Verily Patch
A clinical trial, sponsored by Verily Life Sciences.
- Terminated
- Registry status
- 22
- Enrollment target
NCT04727801: Clinical Trial study, sponsored by Verily Life Sciences.
NCT04727801 is a clinical trial that was terminated before completion, run by Verily Life Sciences. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04727801 was terminated before completion, sponsored by Verily Life Sciences.
- TERMINATED
- Registry status
- 22 participants
- Enrollment target
Study Summary
This is a single center, prospective, non-randomized prospective observational data collection study of the Verily Patch. The Verily Patch is an investigational wearable, continuous temperature sensor which will be evaluated against reference oral and axillary temperature measurements to support development activities for the Verily Patch.
Primary Outcome
Data collection to enable device development of the Verily Patch, which includes the development of an algorithm that estimates temperature
Interventions
- DEVICE Verily Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-03-11 |
| Est. Completion | 2021-05-25 |
Why NCT04727801 stopped before completion
NCT04727801 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Verily Patch is the first listed.
NCT04727801 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04727801 about?
NCT04727801 is a clinical study titled "A Clinical Data Collection Study of Verily Patch". This is a single center, prospective, non-randomized prospective observational data collection study of the Verily Patch. The Verily Patch is an investigational wearable, continuous temperature sensor which will be evaluated against reference oral and axillary temperature measurements to support dev...
What is the current status of trial NCT04727801?
This trial is currently terminated. The enrollment target is 22 participants. The study started on 2021-03-11. Estimated completion is 2021-05-25.
What interventions are being tested in trial NCT04727801?
The interventions under investigation include: Verily Patch (DEVICE).
Who is sponsoring clinical trial NCT04727801?
This trial is sponsored by Verily Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI